Novartis Corporation We want to discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering and to enhance the quality of life.
Novartis offers a wide range of healthcare products through...
Irix Pharmaceuticals IRIX Pharmaceuticals, Inc. is a privately held company engaged in the generation of process technology for new and existing drugs.
IRIX offers the full capability of supplying API's and complex pharma intermediates from...
Targacept, Inc. Targacept, Inc. is a biopharmaceutical company engaged in the design, discovery and development of NNR Therapeutics(TM), a new class of drugs for the treatment of multiple diseases and disorders of the central nervous...
Research and Diagnostic Systems, Inc. R&D Systems was founded in 1976 in Minneapolis, MN. It is a wholly owned subsidiary of TECHNE Corporation (a holding company with no employees). The stock is traded publicly on NASDAQ's National Market System under the...
Molecular Devices Molecular Devices supplies high-performance bioanalytical measurement systems that accelerate and improve drug discovery and other life sciences research. Its systems and consumables enable pharmaceutical and...
This paper explores the opportunities to improve the R&D process. It proposes new technologies will enable the adoption of virtual R&D; and by operating in a more connected world, the industry in collaboration with researchers, governments, healthcare payers and providers, can address the changing needs of society more effectively.
Case: The American Diabetes Association used the Archimedes Model to extend the three-year Diabetes Prevention Program (DPP) trial and compare the long-term effects of current care, metformin, and lifestyle modification on the incidence of diabetes and costs in high-risk individuals.
Conclusion: The Model showed that, after 30 years, the lifestyle modification program would reduce the relative ...
Recent industry analyst reports predict that worldwide pharmaceutical industry revenues will grow at a compound annual growth rate (CAGR) of 8.58% through 2008. Worldwide biotechnology revenues are expected to grow at a compound annual growth rate of 25.96% through 2008 – this large growth rate is not surprising as many biotechnology and biopharmaceutical companies are just now moving products ...
Case: This project calculated the expected event rate in a control population of patients at risk for a Major Adverse Cardiac Event (MACE).
Conclusion: This information enabled a major pharmaceutical company to tune the enrollment optimally in a clinical trial evaluating a candidate compound targeting a novel cardiovascular biomarker.
Case: This project calculated the expected effect on health and economic outcomes of a proposed new program for managing people with diabetes in Kaiser Permanente, called "A-L-L". The Model predicted that the A-L-L program would simultaneously improve the health of Kaiser Permanente's members while also saving an estimated $38 million annually in unnecessary healthcare costs. Given the outcomes ...
Have you ever wanted to run trials for 10 years, 20 years or 60 years? Or run huge trials with hundreds of thousands or even millions of people?
Math is ...
Company descriptions and contact
information are quoted
from the company's website or other promotional information. JAZ'D is not responsible for
the accuracy
of this information. Unless specifically noted, JAZ'D is not sponsored by, affiliated with
or otherwise
connected with any of the listed companies.
